Print Page  Close Window
Investor Overview
Company Overview

PDI is a leading healthcare commercialization company providing superior go-to-market strategy and execution to established and emerging healthcare companies through its three core business units. The company's Sales Services business unit (CSO) is a leading provider of outsourced pharmaceutical, medical device and diagnostics sales teams. PDI's Product Commercialization Services, including Interpace Diagnostics and the ThyGenX NGS Test, provides full product commercialization and is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management. Its Marketing Services division is a pioneer in insight-driven digital c... More >>

Recent News
DateTitle 
05/18/15Interpace Diagnostics Announces New Data Supporting Use of BarreGen™, a Molecular Test for Predicting Risk of Progression from Barrett's Esophagus to Esophageal Cancer
PARSIPPANY, N.J., May 18, 2015 /PRNewswire/ -- PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced today new data demonstrating the clinical value of BarreGen™, a molecular diagnostic test for predicting risk of progression from Barrett's esophagus to esophageal cancer approximately three to four years before the cancer develops. Barrett's esophagus is a condition that occurs when tissue lining the esophagus is replaced by tissue similar to the intestinal lining. It is assoc... 
Printer Friendly Version
05/14/15Interpace Diagnostics Presents New Data at American Association of Clinical Endocrinologists (AACE) Annual Congress Demonstrating Unsurpassed Performance of ThyraMIR™ in Combination with ThyGenX™
Data Show Tests Improve Preoperative Management of Benign Thyroid Nodules with Indeterminate Cytology, Helping Patients Get the Right Surgery the First Time PARSIPPANY, N.J., May 14, 2015 /PRNewswire/ -- PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced data today from two studies showing that ThyraMIR™, a novel microRNA gene expression classifier combined with ThyGenX™,1 Interpace Diagnostics' genetic mutation panel, provides physicians with a unique solution that offer... 
Printer Friendly Version
05/12/15PDI Reports 20% First Quarter 2015 Revenue Growth
-- Strong Commercial Services Q1 Top Line Performance with Solid Pipeline -- April Launch of ThyraMIR, Combined with ThyGenX, Creates Compelling Thyroid Diagnostic Solution -- Updates 2015 Financial Outlook for Double-Digit Revenue Growth -- Conference Call Today, May 12, 2015 at 4:30 pm ET PARSIPPANY, N.J., May 12, 2015 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today reported financial and operational results for the first quarter ended March 31, 2015.  Net revenue for the first q... 
Printer Friendly Version
04/23/15PDI, Inc. to Report 2015 First Quarter Financial Results
PARSIPPANY, N.J., April 23, 2015 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced it will report financial results for its 2015 first quarter ended  March 31, 2015, on Tuesday, May 12, 2015, after the close of the U.S. financial markets. Management will host a conference call beginning at 4:30 p.m. Eastern Time on May 12, 2015, to discuss the results and to answer questions.  Access information: Date: Tuesday, May 12, 2015 ... 
Printer Friendly Version
More >>

Investor Relations Contact:
Doug Sherk
EVC Group
(415) 652-9100
dsherk@evcgroup.com

Media Contact:
Corinne de Palma
CD Public Relations
(212) 399-0887
Corinne@CDPublicrelations.net

Stock Quote
PDII (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.27
Change (%) Stock is Up 0.02 (1.60%)
Volume1,487
Data as of 05/22/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Events and Presentations
Investor Presentation March 2015
Webcasts
Data provided by Nasdaq. Minimum 15 minutes delayed.